Atlas Trials

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

Clinical trial NCT03472274 · COMPLETED

Trial details

NCT number
NCT03472274
Sponsor
Fundacion CRIS de Investigación para Vencer el Cáncer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2018-10-25
Primary completion
2021-04-30
Enrollment
101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.